AbbVie Inc. is a global, diversified research-based biopharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics. Key products include Skyrizi (risankizumab) and Rinvoq (upadacitinib) for autoimmune diseases, Humira (adalimumab), Vraylar (cariprazine) for neurological conditions, Imbruvica (ibrutinib) and Venclexta (venetoclax) for blood cancers, and Botox Cosmetic and Botox Therapeutic for aesthetic and therapeutic applications. AbbVie develops, manufactures, and commercializes therapies addressing complex and serious diseases globally.
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-20 | 2025-12-31 | 0001551152-26-000008 | EDGAR | 71K words |
| 2025-02-14 | 2024-12-31 | 0001551152-25-000020 | EDGAR | 71K words |
| 2024-02-20 | 2023-12-31 | 0001551152-24-000011 | EDGAR | 68K words |
| 2023-02-17 | 2022-12-31 | 0001551152-23-000011 | EDGAR | — |
| 2022-02-18 | 2021-12-31 | 0001551152-22-000007 | EDGAR | — |
| 2021-02-19 | 2020-12-31 | 0001551152-21-000008 | EDGAR | — |
| 2020-02-21 | 2019-12-31 | 0001551152-20-000007 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001551152-19-000008 | EDGAR | — |
| 2018-02-16 | 2017-12-31 | 0001551152-18-000014 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-03 | 2026-06-30 | 0001551152-26-000026 | EDGAR | 22K words |
| 2026-05-08 | 2026-03-31 | 0001551152-26-000017 | EDGAR | 18K words |
| 2025-11-04 | 2025-09-30 | 0001551152-25-000049 | EDGAR | 26K words |
| 2025-08-04 | 2025-06-30 | 0001551152-25-000040 | EDGAR | 25K words |
| 2025-05-09 | 2025-03-31 | 0001551152-25-000029 | EDGAR | 20K words |
| 2024-11-04 | 2024-09-30 | 0001551152-24-000040 | EDGAR | 28K words |
| 2024-08-07 | 2024-06-30 | 0001551152-24-000031 | EDGAR | 26K words |
| 2024-05-03 | 2024-03-31 | 0001551152-24-000020 | EDGAR | 22K words |
| 2023-11-06 | 2023-09-30 | 0001551152-23-000045 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001551152-23-000033 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0001551152-23-000023 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0001551152-22-000045 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-03 | 0001104659-26-104940 | EDGAR | 2K words |
| 2026-08-18 | 0001104659-26-098367 | EDGAR | 43K words |
| 2026-08-05 | 0001104659-26-091269 | EDGAR | 15K words |
| 2026-07-31 | 0001551152-26-000023 | EDGAR | 9K words |
| 2026-07-06 | 0001551152-26-000021 | EDGAR | 0K words |
| 2026-06-22 | 0001104659-26-076067 | EDGAR | 3K words |
| 2026-05-12 | 0001104659-26-059484 | EDGAR | 1K words |
| 2026-04-29 | 0001551152-26-000013 | EDGAR | 5K words |
| 2026-04-03 | 0001551152-26-000011 | EDGAR | 1K words |
| 2026-03-04 | 0001104659-26-023534 | EDGAR | 32K words |
202 total filings indexed. 171 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001551152 |
| Ticker | ABBV |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.abbvie.com |
| Listed | 2012-12-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ABBV (~200 tokens, structured JSON with cryptographic provenance)